查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1719237

左旋多巴市場－全球產業規模、佔有率、趨勢、機會和預測（按銷售管道、最終用途、地區和競爭細分，2020-2030 年）

Levodopa Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球左旋多巴市場價值為 1.7371 億美元，預計到 2030 年將達到 2.7153 億美元，預測期內複合年成長率為 5.36%。左旋多巴仍然是治療帕金森氏症和帕金森氏症相關運動症狀的基礎療法，可顯著改善患者的生活品質。全球帕金森氏症患者病率的上升（主要發生在 60 歲及以上的人群中）是推動市場需求的一個主要因素。根據世界衛生組織 (WHO) 的數據，目前全球有超過 600 萬人患有帕金森氏症，預計隨著人口老化，這一數字還會增加。因此，對左旋多巴療法的需求不斷擴大。雖然像 Sinemet 這樣的品牌藥物仍然保持著強大的品牌認知度，但越來越多具有成本效益的學名藥的採用正在重塑市場動態，尤其是在對價格敏感的新興地區。

市場概覽
預測期 2026-2030
2024年市場規模 1.7371億美元
2030年市場規模 2.7153億美元
2025-2030 年複合年成長率 5.36%
成長最快的領域 直接的
最大的市場 北美洲

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

副作用和長期使用問題

主要市場趨勢

更重視長效和非口服製劑

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球左旋多巴市場的影響

第5章：全球左旋多巴市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按銷售管道（直接、間接）
    • 依最終用途（帕金森氏症、不安腿症候群、運動障礙管理、阿茲海默症、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美左旋多巴市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲左旋多巴市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太左旋多巴市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美左旋多巴市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲左旋多巴市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球左旋多巴市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Wild Wind Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • SHADRI LAB PRIVATE LTD
  • Divi's Laboratories Limited
  • Zhejiang Zhenyuan Co., Ltd.
  • EMBIO LIMITED
  • JK LIFECARE CENTERS PVT. LTD
  • Hetero Drugs Limited

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28581

The Global Levodopa Market was valued at USD 173.71 Million in 2024 and is anticipated to reach USD 271.53 Million by 2030, growing at a CAGR of 5.36% during the forecast period. Levodopa remains a foundational treatment for managing motor symptoms associated with Parkinson's disease and parkinsonism, offering substantial improvements in patients' quality of life. The global rise in Parkinson's disease prevalence-primarily among individuals aged 60 and above-is a major factor fueling market demand. According to the World Health Organization (WHO), over 6 million people currently live with Parkinson's disease, a number projected to grow alongside aging populations. As a result, the need for levodopa-based therapies continues to expand. While branded drugs like Sinemet retain strong brand recognition, increasing adoption of cost-effective generics is reshaping market dynamics, especially in price-sensitive emerging regions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 173.71 Million
Market Size 2030USD 271.53 Million
CAGR 2025-20305.36%
Fastest Growing SegmentDirect
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The global increase in healthcare expenditure is a key factor supporting the levodopa market, particularly in the context of chronic neurological disease management. With healthcare spending reaching USD 9.8 trillion in 2021-accounting for 10.3% of global GDP-governments and private institutions are prioritizing resource allocation for conditions such as Parkinson's disease. Despite such investments, life expectancy remains static in several countries, reinforcing the need for effective chronic care solutions. Levodopa remains the most prescribed therapy for Parkinson's symptoms, and improved healthcare infrastructure-particularly in Asia-Pacific and Latin America-is expanding access to this essential medication. As neurological diseases affect over 3 billion people globally, rising per capita healthcare investment is enabling wider use of levodopa across both established and emerging markets.

Key Market Challenges

Side Effects and Long-Term Use Concerns

A key challenge limiting the long-term use of levodopa is the occurrence of motor complications, such as dyskinesia and motor fluctuations, with prolonged therapy. Although levodopa delivers significant early-stage symptom relief, long-term administration can lead to "on-off" episodes and reduced therapeutic consistency. These adverse effects are caused by fluctuating dopamine levels and can substantially diminish quality of life for advanced-stage patients. Consequently, reliance on levodopa monotherapy decreases over time, pushing the need for combination therapies or reformulated drugs that offer more stable symptom management. These side effects pose significant limitations for clinicians and patients, impacting treatment planning and adherence.

Key Market Trends

Increased Focus on Long-Acting and Non-Oral Formulations

The shift toward long-acting and alternative delivery formulations is becoming a prominent trend in the levodopa market. Traditional oral levodopa often requires multiple doses per day, leading to patient compliance challenges and inconsistent symptom control. Innovations such as extended-release formulations and non-oral delivery systems are designed to address these issues by offering sustained therapeutic effects and improved adherence. For instance, Duodopa-a gel-based levodopa administered via an infusion pump and PEJ tube-provides continuous drug delivery for advanced Parkinson's patients experiencing severe motor fluctuations. These solutions reduce the frequency of dosing and stabilize dopamine levels, mitigating the "on-off" phenomenon. As a result, long-acting options are gaining traction in clinical practice and are expected to contribute significantly to future market growth.

Key Market Players

  • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Wild Wind Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • SHADRI LAB PRIVATE LTD
  • Divi's Laboratories Limited
  • Zhejiang Zhenyuan Co., Ltd.
  • EMBIO LIMITED
  • J.K. LIFECARE CENTERS PVT. LTD
  • Hetero Drugs Limited

Report Scope

In this report, the Global Levodopa Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Levodopa Market, By Sales Channel:

  • Direct
  • Indirect

Levodopa Market, By End Use:

  • Parkinson's Disease
  • Restless Legs Syndrome
  • Dyskinesia Management
  • Alzheimer's Disease
  • Others

Levodopa Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Levodopa Market.

Available Customizations

Global Levodopa Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Levodopa Market

5. Global Levodopa Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Parkinson's Disease, Restless Legs Syndrome, Dyskinesia Management, Alzheimer's Disease, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Levodopa Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Levodopa Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Levodopa Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Levodopa Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Levodopa Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Levodopa Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Levodopa Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Levodopa Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Levodopa Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Levodopa Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Levodopa Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Levodopa Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Levodopa Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Levodopa Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Levodopa Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Levodopa Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Levodopa Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Levodopa Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Levodopa Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Levodopa Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Levodopa Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Levodopa Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Levodopa Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Levodopa Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Levodopa Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Shandong Xinhua Pharmaceutical Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Wild Wind Pharmaceutical
  • 15.3. Zhejiang Huahai Pharmaceutical
  • 15.4. Zhejiang Yefeng Pharmaceutical Co., Ltd
  • 15.5. SHADRI LAB PRIVATE LTD
  • 15.6. Divi's Laboratories Limited
  • 15.7. Zhejiang Zhenyuan Co., Ltd.
  • 15.8. EMBIO LIMITED
  • 15.9. J.K. LIFECARE CENTERS PVT. LTD
  • 15.10. Hetero Drugs Limited

16. Strategic Recommendations

17. About Us & Disclaimer